120 related articles for article (PubMed ID: 21546857)
1. Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.
Bouwhuis MG; Collette S; Suciu S; de Groot ER; Kruit WH; Ten Hagen TL; Aarden LA; Eggermont AM; Swaak AJ;
Melanoma Res; 2011 Aug; 21(4):344-51. PubMed ID: 21546857
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
4. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
5. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
7. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
8. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
[TBL] [Abstract][Full Text] [Related]
9. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
11. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
Stam TC; Swaak AJ; Kruit WH; Eggermont AM
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():79-83. PubMed ID: 11886436
[TBL] [Abstract][Full Text] [Related]
13. Increased ferritin response in adult Still's disease: specificity and relationship to outcome.
Evensen KJ; Swaak TJ; Nossent JC
Scand J Rheumatol; 2007; 36(2):107-10. PubMed ID: 17476616
[TBL] [Abstract][Full Text] [Related]
14. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin.
González AS; Guerrero DB; Soto MB; Díaz SP; Martinez-Olmos M; Vidal O
Eur J Clin Nutr; 2006 Jun; 60(6):802-9. PubMed ID: 16493453
[TBL] [Abstract][Full Text] [Related]
17. Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?
Roberge D; Muanza T; Blake G; Shustik C; Vuong T; Freeman CR
Br J Dermatol; 2007 Jan; 156(1):57-61. PubMed ID: 17199567
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
19. Association of in vitro oxidative stress, serum ferritin concentration and C-reactive protein in febrile emergency room patients.
Huang HH; Yan HC; Han CL; Yu FC; Kao WY; Chen WT
Clin Invest Med; 2005 Apr; 28(2):48-54. PubMed ID: 15909479
[TBL] [Abstract][Full Text] [Related]
20. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
